Glucose lowering and cardiovascular disease: what do we know and what should we do?

被引:10
作者
Cheng, Alice Y. Y.
Leiter, Lawrence A. [1 ]
机构
[1] Univ Toronto, Div Endocrinol & Metab, Toronto, ON M5C 2T2, Canada
来源
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION | 2010年 / 17卷
关键词
diabetes mellitus; cardiovascular disease; glucose control; glycemic control; MULTIFACTORIAL INTERVENTION; FOLLOW-UP; TYPE-2; DEATH;
D O I
10.1097/01.hjr.0000368194.32356.5f
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
For the reduction of microvascular complications in type 2 diabetes, glycemic control has been shown to be an important and effective intervention. However, considering the findings from several recent, large, randomized controlled trials, the utility of very tight glycemic control in all those with type 2 diabetes, for the reduction of cardiovascular disease remains controversial. The decision to aim for very tight glycemic control must be individualized and the potential benefit of reduced risk of nephropathy must be weighed against the increased risk for hypoglycemia. The results of the 10-year post-trial monitoring of the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated macrovascular benefits of glycemic control in newly diagnosed type 2 diabetes but lengthy follow-up was required to demonstrate the effect. This raises the possibility that benefits of glucose lowering to reduce cardiovascular risk is more evident in those with a shorter duration of diabetes and requires many years to manifest. For the time being, there remains good evidence for targeting A1c < 7% for microvascular protection but attempts to lower A1c beyond this must be considered on an individual basis. Eur J Cardiovasc Prev Rehabil 17 (Suppl 1): S25-S31 (C) 2010 The European Society of Cardiology
引用
收藏
页码:S25 / S31
页数:7
相关论文
共 22 条
  • [1] [Anonymous], IDF DIAB ATL
  • [2] A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
    Frye R.L.
    August P.
    Brooks M.M.
    Hardison R.M.
    Kelsey S.F.
    MacGregor J.M.
    Orchard T.J.
    Chaitman B.R.
    Genuth S.M.
    Goldberg S.H.
    Hlatky M.A.
    Jones T.L.Z.
    Molitch M.E.
    Nesto R.W.
    Sako E.Y.
    Sobel B.E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (24) : 2503 - 2515
  • [3] Action to control cardiovascular risk in diabetes (ACCORD) trial: Design and methods
    Buse, John B.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (12A) : 21I - 33I
  • [4] Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview
    Capes, SE
    Hunt, D
    Malmberg, K
    Gerstein, HC
    [J]. LANCET, 2000, 355 (9206) : 773 - 778
  • [5] Intensive glycemic control in the ACCORD and ADVANCE trials
    Dluhy, Robert G.
    McMahon, Graham T.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24) : 2630 - 2633
  • [6] Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
    Duckworth, William
    Abraira, Carlos
    Moritz, Thomas
    Reda, Domenic
    Emanuele, Nicholas
    Reaven, Peter D.
    Zieve, Franklin J.
    Marks, Jennifer
    Davis, Stephen N.
    Hayward, Rodney
    Warren, Stuart R.
    Goldman, Steven
    McCarren, Madeline
    Vitek, Mary Ellen
    Henderson, William G.
    Huang, Grant D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (02) : 129 - U62
  • [7] Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
    Gaede, P
    Vedel, P
    Larsen, N
    Jensen, GVH
    Parving, H
    Pedersen, O
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05) : 383 - 393
  • [8] Effect of a multifactorial intervention on mortality in type 2 diabetes
    Gaede, Peter
    Lund-Andersen, Henrik
    Parving, Hans-Henrik
    Pedersen, Oluf
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (06) : 580 - 591
  • [9] Gerstein H C, 1997, Evid Based Cardiovasc Med, V1, P87, DOI 10.1016/S1361-2611(97)80002-4
  • [10] Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743